Thermo Fisher Scientific Inc. $TMO Shares Bought by Cypress Wealth Services LLC

Key Points

• Cypress Wealth Services LLC increased its stake in Thermo Fisher Scientific by 114.2% during the 2nd quarter, taking its total holdings to 1,416 shares valued at $574,000.
• Several institutional investors significantly boosted their stakes in Thermo Fisher, with notable investments including Nuveen LLC's new stake worth approximately $532 million.
• Thermo Fisher reported earnings of $5.36 per share, surpassing analysts' expectations, and projected Q3 and FY 2025 guidance for earnings per share between $5.460-5.510 and $22.220-22.840, respectively.

Cypress Wealth Services LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 114.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,416 shares of the medical research company's stock after buying an additional 755 shares during the quarter. Cypress Wealth Services LLC's holdings in Thermo Fisher Scientific were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $532,360,000. EdgePoint Investment Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $172,139,000. Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 6,655.5% during the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after buying an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after buying an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co lifted its stake in shares of Thermo Fisher Scientific by 6,773.5% during the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock valued at $143,309,000 after buying an additional 283,810 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

TMO opened at $524.80 on Tuesday. The company has a fifty day simple moving average of $489.83 and a 200 day simple moving average of $447.66. The firm has a market cap of $198.17 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TMO shares. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Barclays upped their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Finally, HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $589.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.